US SEC Filings Daily Market Digest — February 27, 2026
Across 298 SEC filings dated February 27, 2026, a dominant theme is earnings season with 50+ Item 2.02 disclosures (e.g., Amneal Pharma, Cigna, BrightSpring), mostly neutral due to undisclosed metrics, signaling steady but unremarkable Q4/FY2025 results amid quiet markets. Portfolio-level trends show mixed performance: revenues grew YoY in detailed reporters like US Antimony (record highs), Precipio (+30%), American Integrity (+23% premiums), but declined in others like Where Food Comes From (-3.3%), Gogo (ATG aircraft -9%); margins compressed in REITs/hospitality (Apple Hospitality EBITDA -190 bps) while improving in insurance (American Integrity combined ratio -17 ppts). Critical developments include 5 delistings/notices (Datavault AI, reAlpha Tech, Envoy Medical bearish; Sphere 3D regains compliance bullish), $2.8B Netflix termination fee from failed WBD deal, and $200M+ capital raises/debt refinancings (Tandem Diabetes, Ameren $891M bonds, Wyndham $650M notes). M&A activity surged with 20+ Item 1.01 (e.g., Amazon, AIR Industries neutral), insider changes neutral, but positive capital allocation via dividends/buybacks in 15+ (Healthcare Realty $50M repurchases, REIT distributions). Sector patterns favor energy/mining (US Antimony contracts), REITs (guidance intact), but flag biotech delistings and accounting restatements (Elauwit non-reliance). Implications: Favor defensive dividend payers/turnarounds; avoid small-cap delisting risks; monitor Q1 guidance for margin trends.